THE WOODLANDS, Texas, June 17, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has commenced an underwritten public offering of up to 3,000,000 shares of its common stock. All of the shares in the offering are to be sold by Repros Therapeutics Inc.
BofA Merrill Lynch is acting as the sole book-running manager for the offering and Lazard Capital Markets LLC, Ladenburg Thalmann & Co. Inc. and Ascendiant Capital Markets, LLC are acting as co-managers in the offering. Repros Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold. The offering is subject to market conditions which may delay or prevent the offering from being completed, or impact the actual size or terms of the offering.
The securities described above are being offered by Repros Therapeutics pursuant to an existing shelf registration statement that Repros Therapeutics filed with the Securities and Exchange Commission ("SEC").This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The offering may be made only by means of a prospectus supplement and accompanying base prospectuses meeting the requirements of Section 10 of the Securities Act of 1933, as amended. A preliminary prospectus supplement related to the offering is expected to be filed with the SEC and, if and when filed, will be available, free of charge, on the SEC's website located at www.sec.gov . Alternatively, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from the offices of: BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attention: Prospectus Department or by emailing email@example.com. The final terms of the offering will be disclosed in a final prospectus supplement filed with the SEC. Before you invest, you should read the prospectus, the related prospectus supplement and the documents incorporated by reference therein with respect to the offering and any other document Repros Therapeutics has filed with the SEC for more complete information about Repros Therapeutics and the offering. About Repros Therapeutics Inc. Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts